Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib

Annals of Oncology

Volumn 21, Issue 1, 2009, Pages 184-185

  Overkleeft, E N M ^a   Goldschmeding, R ^a   van Reekum, F ^a   Voest, E E ^a   Verheul, H M W ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SORAFENIB;

ADULT; ADVANCED CANCER; CASE REPORT; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; ERYTHROCYTE; FLU LIKE SYNDROME; GENERALIZED EDEMA; GLOMERULUS FILTRATION RATE; HEMATURIA; HUMAN; HYPERTENSION; KIDNEY BIOPSY; KIDNEY CARCINOMA; KIDNEY FAILURE; KIDNEY FUNCTION; LETTER; MALE; NEPHROTIC SYNDROME; OLIGURIA; PRIORITY JOURNAL; PROTEINURIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 77949326926     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp472     Document Type: Letter

References (6)

1. Escudier B, Eisen T, Walter M et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
2. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7: 475-485.
3. Hirschberg R, Wang S, Mitu GM. Functional symbiosis between endothelium and epithelial cells in glomeruli. Cell Tissue Res 2007; 331: 485-493.
4. Patel T, Morgan JA, Demetri GD et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 2008; 100: 282-284.
5. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-1136.
6. Kapiteijn E, Brand A, Kroep J et al. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 2007; 18: 1745-1747.